Jevtana
Jevtana
$10,000.00
Jevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing treatment regimen.
Author: Zachary McLella
Publisher: Datamonitor Healthcare
- Description
- Contents
Drug Overview
Jevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing treatment regimen. By promoting tubulin assembly into microtubules while simultaneously preventing disassembly, Jevtana inhibits mitotic and interphase cellular functions, non-specifically inhibiting cell replication.
TABLE OF CONTENTS
4 Product Profiles
4 Jevtana : Prostate cancer
LIST OF FIGURES
9 Figure 1: Jevtana for prostate cancer – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Jevtana for prostate cancer
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Jevtana for prostate cancer
13 Figure 4: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
4 Table 1: Jevtana drug profile
6 Table 2: Jevtana pivotal Phase III data in prostate cancer
8 Table 3: Jevtana Phase III data in prostate cancer
14 Table 4: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
